Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARMic: Restrictive Antibiotic Strategy in CAR-T Cell Therapy
NCT07842198Phase 2Not yet recruiting
- Sponsor
- Zealand University Hospital
- Start
- Mar 2027
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ceftazidime and ciprofloxacin in bacterial infection (2 arms), sponsored by Zealand University Hospital. Primary endpoint: Gut Microbiota Alpha Diversity at Day 28. Planned start Mar 2027; status: not yet recruiting.
02
Drugs
ceftazidimeciprofloxacin
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT07842198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07842198.